GOT-IT Trial: Glyceryl Trinitrate for Retained Placenta (GOT-IT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02085213|
Recruitment Status : Completed
First Posted : March 12, 2014
Last Update Posted : May 21, 2018
A retained placenta (RP) is a complication after a normal birth, which affects nearly 11,000 women in the UK per year. This is where the placenta is not delivered spontaneously after giving birth. It is a major cause of postpartum haemorrhage (major loss of blood) which can lead to the death of the mother. The recommended treatment for RP is a surgical procedure - manual removal of placenta (MROP). This is a painful and unpleasant intervention for the women, involving additional hospital stay, and is an expensive outcome for the NHS. It is widely recognised that non-surgical management options for RP are limited and it has been recommended that research is needed into new medical treatments for RP. New effective treatments for RP would dramatically reduce the number of women requiring MROP with the operation being restricted to the small minority of women with particularly stuck placentae. The reduction in operative interventions would have cost benefits for the NHS and also for women in terms of increased satisfaction, less separation of mother and baby immediately after birth, and reduced morbidity.
This study will try to prove the clinical and cost effectiveness of a known treatment for angina, Glyceryl trinitrate (GTN) used to treat RP. The investigators will compare GTN against a placebo (dummy treatment) in a randomised controlled blinded trial (GOT-IT).
The GOT-IT Trial will be conducted in two phases. The first phase will involve an internal pilot study where the aim will be to test out and refine trial procedures in a small number of hospital sites. The second phase will be the main trial where recruitment will be extended to a larger number of hospitals in order to determine clinical and cost effectiveness.
|Condition or disease||Intervention/treatment||Phase|
|Placenta, Retained||Drug: Glyceryl Trinitrate Drug: Matched Placebo||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||1107 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||Triple (Participant, Investigator, Outcomes Assessor)|
|Official Title:||GOT-IT Trial: A Pragmatic Group Sequential Placebo Controlled Randomised Trial to Determine the Effectiveness of Glyceryl Trinitrate for Retained Placenta.|
|Study Start Date :||September 2014|
|Actual Primary Completion Date :||July 26, 2017|
|Actual Study Completion Date :||October 5, 2017|
Experimental: Glyceryl Trinitrate
Nitrolingual Pump Spray [Coro-Nitro] A liquid within non-pressurised, red plastic-coated glass bottle fitted with a pump capable of delivering a metered dose containing 400μg of glyceryl trinitrate.
Excipients: The formulation contains fractionated coconut oil, absolute ethanol, medium chain partial glycerides and peppermint oil.
The treatment will be self administered (2 puffs) as a single intervention. No second intervention will be given.
Drug: Glyceryl Trinitrate
Other Name: GTN
Placebo Comparator: Placebo
Matched placebo formulation (except for active ingredient of Glyceryl Trinitrate) with matched packaging and labelling.
Drug: Matched Placebo
Other Name: Dummy treatment
- Need for Manual Removal of Placenta [ Time Frame: From time of randomisation up to 15-minutes post administration of study treatment ]Defined as the placenta remaining undelivered 15 minutes post study treatment and/or being required within 15 minutes of treatment due to safety concerns.
- Fall in haemoglobin [ Time Frame: First postnatal day (approximately 24 hours since the birth). ]Fall in haemoglobin of more than 15% between recruitment and the first postnatal day.
- Time from randomisation to delivery of placenta. [ Time Frame: From time of randomisation and administration of the study treatment to delivery of placenta (up to approximately 2 hours). ]The time from when the study drug is administered until the placenta is delivered.
- Need for earlier than planned MROP on the basis of the clinical condition. [ Time Frame: From time of randomisation and administration of the study treatment to delivery of placenta (up to approximately 2 hours). ]This will measure how many women required to go to theatre as an emergency before the 15 minute trial has been completed.
- Systolic and diastolic blood pressure. [ Time Frame: Study treatment to 15 minutes postadministration. ]Fall in systolic or diastolic blood pressure of more than 15mmHg and/or increase in pulse of more than 20 beats/minute between baseline and 5 and 15 minutes postadministration of active/placebo treatment.
- Need for blood transfusion [ Time Frame: From the time of delivery of the placenta to time of discharge from hospital (up to 7 days). ]How many women will be required to have a blood transfusion between time of delivery and hospital discharge.
- Need for general anaesthesia [ Time Frame: From time of randomisation and administration of the study treatment to delivery of placenta (up to approximately 2 hours). ]Will measure how many women required a general anaesthetic from when the study drug was administered until the placenta was delivered.
- Maternal Pyrexia [ Time Frame: Within 72 hours of delivery or discharge from hospital if discharge occurs sooner ]One or more temperature reading of more than 38°C.
- Sustained uterine relaxation. [ Time Frame: Within 24 hours of the time of delivery of the placenta. ]Sustained uterine relaxation after removal of placenta requiring uterotonics.
- Mean costs for each treatment allocation group [ Time Frame: 6 weeks. ]The mean costs will be summarised by treatment allocation group, and the incremental cost (cost saving) associated with the use of GTN will be estimated using an appropriately specified general linear model. The cost data will be presented alongside the primary and secondary outcome data in a cost-consequence balance sheet, indicating which strategy each outcome favours.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02085213
|Royal Infirmary of Edinburgh|
|Edinburgh, Midlothian, United Kingdom, EH16 4TJ|
|Principal Investigator:||Fiona C Denison, Dr||The University of Edinburgh|